Long-Term Follow-Up of MonumenTAL-1
Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.
EP: 1.Significance of GPRC5D as a Target for R/R MM
Now Viewing
EP: 2.Long-Term Follow-Up of MonumenTAL-1
EP: 3.MonumenTAL-1: Efficacy and Safety Data
EP: 4.Broader Implications and Current Trials of GPRC5D-Targeted Treatments in Relapsed/Refractory Multiple Myeloma
EP: 5.Overview of MonumenTAL-2 and MonumenTAL-3
EP: 6.Evaluating Combination Strategies in R/R MM: TRIMM-2, TRIMM-3, MajesTEC-3
EP: 7.Exploring GPRC5D as an Important Target for Multiple Myeloma
EP: 8.Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5
EP: 9.Implications of Combination Regimens for R/R MM
EP: 10.Overview of Recent Updates in Bispecific Therapy in R/R MM
EP: 11.Impact of T-cell Affinity in Bispecific Therapy in R/R MM
Video content above is prompted by the following:
- Please discuss the efficacy data, focusing on PFS and DOR, presented at EHA 2024 on the long-term follow-up results of the phase 1/2 MonumenTAL-1 study of talquetamab in patients with RRMM.
- What factors might contribute to the longer DOR with Q2W dosing compared to QW dosing in patients naive to prior TCR?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
